Last reviewed · How we verify
CoFactor
At a glance
| Generic name | CoFactor |
|---|---|
| Also known as | ANX-510 |
| Sponsor | Mast Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Ascorbate in Myelodysplastic Syndrome (PHASE2)
- PQQ for Cognitive and Negative Symptoms (NA)
- KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia (PHASE1)
- Von Willebrand Factor in Pregnancy (VIP) Study
- Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Version Testing of EnzySystem Version A for Hemophilia A
- A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma (PHASE1)
- RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CoFactor CI brief — competitive landscape report
- CoFactor updates RSS · CI watch RSS
- Mast Therapeutics, Inc. portfolio CI